Noble Financial Increases GeoVax Labs (NASDAQ:GOVX) Price Target to $10.00

GeoVax Labs (NASDAQ:GOVX) had its target price lifted by equities researchers at Noble Financial from $6.00 to $10.00 in a report issued on Monday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Noble Financial’s price target indicates a potential upside of 76.06% from the stock’s previous close.

Several other analysts have also commented on the company. Roth Capital raised GeoVax Labs to a “strong-buy” rating in a report on Tuesday, July 16th. EF Hutton Acquisition Co. I raised GeoVax Labs to a “strong-buy” rating in a research report on Tuesday, July 23rd. Roth Mkm assumed coverage on shares of GeoVax Labs in a research report on Tuesday, July 16th. They set a “buy” rating and a $20.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of GeoVax Labs in a report on Monday, August 12th. Three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, GeoVax Labs has a consensus rating of “Buy” and a consensus price target of $12.67.

GeoVax Labs Stock Down 20.6 %

GOVX opened at $5.68 on Monday. GeoVax Labs has a 1 year low of $1.09 and a 1 year high of $11.18. The stock has a 50-day moving average price of $2.70 and a 200-day moving average price of $2.20.

GeoVax Labs (NASDAQ:GOVX) last issued its earnings results on Tuesday, August 6th. The company reported ($1.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.57) by $0.58. The firm had revenue of $0.30 million during the quarter. During the same period in the previous year, the business earned ($3.30) earnings per share. As a group, equities research analysts expect that GeoVax Labs will post -7.41 EPS for the current fiscal year.

Institutional Trading of GeoVax Labs

A hedge fund recently bought a new stake in GeoVax Labs stock. Armistice Capital LLC acquired a new stake in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned 91.38% of GeoVax Labs at the end of the most recent quarter. 6.09% of the stock is owned by hedge funds and other institutional investors.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.